推薦產品
品質等級
化驗
≥98% (HPLC)
形狀
powder
光學活性
[α]/D 40 to 50°, c = 0.5 in methanol
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
−20°C
SMILES 字串
[H][C@@]12[C@@](C[C@@H](O)[C@@H]2CC[C@@H](O)CCCCC)([H])CC3=C(OCC(O)=O)C=CC=C3C1
InChI
1S/C23H34O5.Na/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25;/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27);/q;+1/p-1/t16-,17-,18+,19-,21+;/m1./s1
InChI 密鑰
IQKAWAUTOKVMLE-DQHZMXPSSA-M
生化／生理作用
Synthetic analog of prostacyclin (prostaglandin PGI2); vasodilator used for the treatment of pulmonary arterial hypertension
Treprostinil elicits a longer half-life when compared with iloprost.[1] It mediates inhibition of transforming growth factor-β (TGF-β) and nuclear factor-κB (NF-κB) signaling pathways.[1] Treprostinil effectively reduces right ventricular systolic pressure and inhibits the recruitment of circulating fibrocyte.[2]
Treprostinil is a stable synthetic analog of prostacyclin (prostaglandin PGI2), an IP receptor agonist used clinically for the treatment of pulmonary arterial hypertension. It is a potent vasodilator with antithrombotic, antiproliferative and anti-inflammatory properties.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
分析證明 (COA)
Lot/Batch Number
Ming-Kai Tsai et al.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 62(2), 332-339 (2014-01-10)
Inflammation plays critical roles in atherosclerosis. Chemokines are responsible for leukocyte trafficking and involve in inflammatory diseases. Macrophage inflammatory protein 1α (MIP-1α) has been implicated in atherosclerotic lesion formation. Prostaglandin I2 (PGI2) analog, used in pulmonary hypertension, has been reported
Robert Roscigno et al.
Pulmonary circulation, 10(4), 2045894020971509-2045894020971509 (2020-12-08)
A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy. Treprostinil is a synthetic prostacyclin analogue that is currently approved for inhalation administration to patients with pulmonary arterial hypertension via nebulized
Aaron Waxman et al.
The New England journal of medicine, 384(4), 325-334 (2021-01-14)
No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled treprostinil for patients with this condition are unclear. We enrolled patients with interstitial lung disease and pulmonary
Lucas M Kimmig et al.
Lung, 198(1), 53-58 (2020-01-09)
The intravenous or subcutaneous delivery of prostanoid drugs for moderate to severe pulmonary arterial hypertension has been fraught with complications and patient dissatisfaction. Combination therapy including inhaled treprostinil is an attractive alternative in clinically stable patients. Uncertainties exist about the
Longfei Wang et al.
Arteriosclerosis, thrombosis, and vascular biology, 40(6), 1543-1558 (2020-04-10)
Pulmonary hypertension (PH) due to left heart disease (group 2), especially in the setting of heart failure with preserved ejection fraction (HFpEF), is the most common cause of PH worldwide; however, at present, there is no proven effective therapy available
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
